{"entity":{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","aka":[],"tldr":"Proteomics and mass-cytometry company that merged with SomaLogic (SomaScan aptamer proteomics) in 2024.","summary":"Standard BioTools, based in South San Francisco and listed as LAB, is a proteomics and mass cytometry company that merged with SomaLogic, maker of the SomaScan aptamer proteomics assay, in 2024. Its products include the SomaScan assay measuring around eleven thousand proteins, CyTOF mass cytometry and Hyperion imaging mass cytometry. OnCo links it to proteomics instruments and affinity platforms. Whether large-scale plasma proteomics yields cancer detection or prognostic tests that reach the clinic is the open question. The proteomics instruments page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.standardbio.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["proteomics-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"diagnostics","website":"https://www.standardbio.com","ticker":"LAB","investors":[],"funding":[]},"route":"/companies/standard-biotools/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/"}]}}